Correlation Between Bank Central and Aeglea Bio

Can any of the company-specific risk be diversified away by investing in both Bank Central and Aeglea Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bank Central and Aeglea Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bank Central Asia and Aeglea Bio Therapeutics, you can compare the effects of market volatilities on Bank Central and Aeglea Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bank Central with a short position of Aeglea Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bank Central and Aeglea Bio.

Diversification Opportunities for Bank Central and Aeglea Bio

-0.76

Correlation Coefficient

Bank Central  Aeglea Bio

Pay attention - limited upside

The 3 months correlation between Bank and Aeglea is -0.76. Overlapping area represents the amount of risk that can be diversified away by holding Bank Central Asia and Aeglea Bio Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aeglea Bio Therapeutics and Bank Central is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bank Central Asia are associated (or correlated) with Aeglea Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aeglea Bio Therapeutics has no effect on the direction of Bank Central i.e., Bank Central and Aeglea Bio go up and down completely randomly.

Pair Corralation between Bank Central and Aeglea Bio

Assuming the 90 days horizon Bank Central Asia is expected to generate 1.47 times more return on investment than Aeglea Bio. However, Bank Central is 1.47 times more volatile than Aeglea Bio Therapeutics. It trades about 0.03 of its potential returns per unit of risk. Aeglea Bio Therapeutics is currently generating about -0.58 per unit of risk. If you would invest  1,485  in Bank Central Asia on September 12, 2024 and sell it today you would earn a total of  152.00  from holding Bank Central Asia or generate 10.24% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	0.85%
Values	Daily Returns

Bank Central Asia  vs.  Aeglea Bio Therapeutics

Bank Central Asia

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Bank Central Asia has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Bank Central is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Aeglea Bio Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Aeglea Bio Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound essential indicators, Aeglea Bio is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders.

Pair Trading with Bank Central and Aeglea Bio

The main advantage of trading using opposite Bank Central and Aeglea Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bank Central position performs unexpectedly, Aeglea Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aeglea Bio will offset losses from the drop in Aeglea Bio's long position.

The idea behind Bank Central Asia and Aeglea Bio Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.